reports
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwrigh...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference on Monday, May 20th at 2:30 p.m. ET. The live webcast can be accessed via the Investors section of the Silence website at . An archived replay of the webcast will be available following the conference. About Silence Th...
Silence Therapeutics Announces Retirement of Alistair Gray from Board ...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc (Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that Alistair Gray, who has served as an independent member of Silence’s Board of Directors (the “Board”) since 2015, informed the Company that he will retire from the Board, effective May 1, 2024. Iain Ross, Silence’s Chairman of the Board, commented, “Alistair has made significant contributions to the Board and the Company over ...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
RGLD ROYAL GOLD INC
URI UNITED RENTALS INC.
DOV DOVER CORPORATION
MTH MERITAGE HOMES CORPORATION
MRK MERCK & CO. INC.
FORM FORMFACTOR INC.
CPF CENTRAL PACIFIC FINANCIAL CORP.
CHDN CHURCHILL DOWNS INCORPORATED
AR ANTERO RESOURCES CORPORATION
UVSP UNIVEST FINANCIAL CORPORATION
VIRT VIRTU FINANCIAL INC. CLASS A
NOC NORTHROP GRUMMAN CORPORATION
CECE CECO ENVIRONMENTAL CORP.
CMG CHIPOTLE MEXICAN GRILL INC.
PI IMPINJ INC.
MRUS MERUS B V
ADES ADVANCED EMISSIONS SOLUTIONS
HCC WARRIOR MET COAL INC.
FCNCA FIRST CITIZENS BANCSHARES INC. CLASS A
KDP KEURIG DR PEPPER INC.
MMMB MAMAMANCINI'S HOLDINGS INC
FXI ISHARES CHINA LARGE-CAP ETF
STRA STRATEGIC EDUCATION INC.
DELL DELL TECHNOLOGIES INC CLASS C
TNK TEEKAY TANKERS
AIMD.P AIM4 VENTURES
ALXO ALX ONCOLOGY HOLDINGS
CSU CAPITAL SENIOR LIVING
LRN STRIDE INC
VRT VERTIV HOLDINGS CO (A)
AMR ALPHA METALLURGICAL RESOURCES INC
RSVR RESERVOIR MEDIA
CADL INC.
SG CANDEL THERAPEUTICS INC
EEMA SWEETGREEN INC
CASH ONTO INNOVATION INC.
FEBO ISHARES MSCI EMERGING MARKETS ASIA INDEX
METC HORIZONS HIGH INTEREST SAVINGS ETF
PROP FENBO HOLDINGS LIMITED
AESI RAMACO RESOURCES INC.
PRAIRIE OPERATING CO.
ATLAS ENERGY SOLUTIONS INC CL A
Silence Therapeutics Announces JAMA Publication of Additional Phase 1 ...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced additional results from the APOLLO phase 1 study of zerlasiran (SLN360) in subjects with baseline lipoprotein(a), or Lp(a), levels at or over 150 nmol/L were published in the Journal of the American Medical Association (JAMA), Zerlasiran is a siRNA (short interfering RNA) designed to lower the body’s production of Lp(a), a key gen...
- Gary Brode
Moody's Ratings affirms J&J's Aaa ratings; stable outlook
Moody's Ratings (Moody's) affirmed the ratings of Johnson & Johnson ("J&J") including the Aaa long-term issuer rating, Aaa senior unsecured rating, (P)Aaa senior unsecured medium term note program rating and Prime-1 commercial paper rating. The outlook remains stable. This rating action follows th...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
XBIT XBIOTECH
UFPT UFP TECHNOLOGIES
TRIP TRIPADVISOR INC.
TPH TRI POINTE HOMES INC.
PSX PHILLIPS 66
MTRX MATRIX SERVICE COMPANY
MSA MSA SAFETY INC.
MRK MERCK & CO. INC.
ISRG INTUITIVE SURGICAL INC.
HUBB HUBBELL INCORPORATED CLASS B
GPK GRAPHIC PACKAGING HOLDING COMPANY
FRPT FRESHPET INC
FANG DIAMONDBACK ENERGY INC.
DY DYCOM INDUSTRIES INC.
COLL COLLEGIUM PHARMACEUTICAL INC.
AL AIR LEASE CORPORATION CLASS A
ALV ALLIANZ SE
GBL GAMCO INVESTORS
CW CURTISS-WRIGHT CORPORATION
MPC. MADISON PACIFIC PROPERTIES INC. CL B
ELY CALLAWAY GOLF COMPANY
TG TREDEGAR CORP.
TAYD TAYLOR DEVICES INC.
HWKN HAWKINS INC.
FSTR L.B. FOSTER CO.
TEC TECHNIPFMC PLC
STRA STRATEGIC EDUCATION INC.
MRVI MARAVAI LIFESCIENCES HOLDINGS
SMLP SUMMIT MIDSTREAM PARTNERS
SGC ONTO INNOVATION INC.
SG CAPITAL PUBLIC COMPANY LIMITED
Johnson & Johnson: 1 director
A director at Johnson & Johnson sold 8,891 shares at 162.160USD and the significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Silence Therapeutics Reports Full Year 2023 Financial Results and Rece...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today reported its financial results for the full year ended December 31, 2023, and reviewed recent business highlights. “2023 was a year of strong execution across Silence as we advanced our proprietary pipeline in the clinic,” said Craig Tooman, President and CEO of Silence. “That’s clearly bearing fruit today with the positive topline 36-week d...
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongo...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced positive topline 36-week data from the ongoing ALPACAR-360 phase 2 study of zerlasiran (SLN360) in 178 subjects with baseline lipoprotein(a), or Lp(a), levels at or over 125 nmol/L at high risk of atherosclerotic cardiovascular disease (ASCVD) events. Zerlasiran is a siRNA (short interfering RNA) designed to lower the body’s producti...
Moody's affirms Alkermes' Ba3 CFR, outlook stable
Moody's Investors Service ("Moody's") affirmed the ratings of Alkermes, Inc., a subsidiary of Alkermes plc (collectively "Alkermes"). The affirmed ratings include the Ba3 Corporate Family Rating, the Ba3-PD Probability of Default Rating, and the Ba3 senior secured term loan rating. There is no chang...
Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Resul...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2023, on Wednesday, March 13, 2024. Management will host a conference call at 8:00 a.m. EDT / 12:00 p.m. GMT that day to discuss the Company’s financial results and provide a general business update. The conferen...
Silence Therapeutics Achieves $10 Million Milestone Payment from Astra...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that the initiation by AstraZeneca of a phase 1 clinical trial of the first product candidate under its siRNA (short interfering RNA) collaboration, has triggered a $10.0 million milestone payment to Silence. “This represents the first clinical milestone under our collaboration with AstraZeneca and the third program to enter the cl...
Silence Therapeutics Announces Oversubscribed $120 Million Private Pla...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc (Nasdaq: SLN) (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced an oversubscribed private placement of 5,714,286 of the Company’s American Depositary Shares (“ADSs”)1 at a purchase price of US $21.00 per ADS, representing a premium of approximately 11% to Silence’s 30-day volume-weighted average price, with both new and existing institutional and accredited investors (the “Private Placement”). S...
Merck & Co Inc: 2 directors
Two Directors at Merck & Co Inc sold after exercising options/sold 100,193 shares at between 126.649USD and 126.968USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all t...
Silence Therapeutics to Participate in Fireside Chat at Guggenheim Hea...
LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Wednesday, February 7th at 1:30 p.m. ET. The live webcast can be accessed via the Investors section of the Silence website at . An archived replay of the webcast will be available following the conference. About S...
- MarketLine Department
Saponia dd - Company Profile and SWOT Analysis
Summary Saponia dd - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Saponia dd (Saponia) is a manufacturer of home care and personal hygiene products. The company’s product portfolio comprises dish detergents, laundry detergents, toothbrushes, baby care, hand cream, shaving ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.